Which companies are Sinotherapeutics's closest peers?

The cockpit's peer set: Valneva (VLA.PA), Hvsen Biotechnology (300871.SZ), Liaoning Dingjide Petrochemical (603255.SS), Beijing Scitop Bio-Tech (300858.SZ), Beijing Bohui Innovation Biotechnology (300318.SZ), LongBio Pharma (Suzhou) (1779.HK), HanchorBio (7827.TW), Faeth Therapeutics (FTH).

How has Sinotherapeutics stock performed?

Over six months to 6 Nov 2026 the shares returned -14.2% against -9.5% for the median peer; over one year -26.2%.

← CockpitCompetitor Analysis › 688247.SS Sinotherapeutics, Inc. Class AOpen in the cockpit ↗

Sinotherapeutics, Inc. Class A688247.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum neutral 60

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$537M

US dollars, full cap

Free float

21%

of shares outstanding

$/day

$6.42M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-1.8 pp

WACC 5.6%

Hurdle

+25 pp

Req g minus delivered

Close · CNYCN¥7.98

1D-2.7%

1W+1.5%

1M-17.1%

3M+0.8%

6M-14.2%

YTD-17.7%

1Y-26.2%

ATR %5.5%

52w lowhigh30.4% off high

What Sinotherapeutics does

Employees: 319

Sinotherapeutics at a glance

Size Sinotherapeutics (688247.SS) is a China Health Care company (Biotechnology) with a market value of $537M, the 3690th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.98 on 6 Nov 2026.

Performance Over six months the shares fell 14.2%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 18 in its peer set.

Growth Revenue fell 17.2% over the last twelve months (peer median -1.4%); the operating margin is -0.2% (peer median -55.5%).

Valuation It trades at 7.0× enterprise value to sales against a peer median of 9.6× (7th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.8 points below its cost of capital (5.6% WACC).

Relative performance

Six months, rebased to 100: Sinotherapeutics against the median of its 20 peers (local-currency closes).

Sinotherapeutics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥398M	CN¥446M	CN¥511M	CN¥300M	CN¥248M
Revenue growth	—	-13%	+71%	+21%	—
Gross profit	CN¥168M	CN¥159M	CN¥251M	CN¥154M	CN¥158M
EBITDA	n/a	CN¥66.7M	CN¥144M	CN¥66.7M	CN¥85.3M
Net income	CN¥18.1M	CN¥47.5M	CN¥128M	CN¥61.1M	CN¥92.9M
Free cash flow	CN¥88.7M	CN¥63.4M	CN¥46.3M	-CN¥10.2M	-CN¥96.3M
Capital expenditure	CN¥26.2M	CN¥41.6M	CN¥94.9M	CN¥39.0M	CN¥176M
Total debt	CN¥38,667	CN¥22,551	CN¥6,393	CN¥85,103	CN¥1.52M

Quarterly statements and history in the cockpit →

Sinotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Sinotherapeutics is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sinotherapeutics is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sinotherapeutics is the large dot.

Sinotherapeutics competitors and peer comparison

How Sinotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sinotherapeutics against its 20 peers (data as of 6 Nov 2026)
Measure	688247.SS	Peer median	Rank in peer set
1-month return	-17.1%	-12.2%	7th lowest of 21
6-month return	-14.2%	-9.5%	8th lowest of 18
Distance from 52-week high	-30.4%	-44.9%	2nd highest of 21
Revenue growth (TTM)	-17.2%	-1.4%	5th lowest of 14
Operating margin	-0.2%	-55.5%	5th highest of 15
EV / Sales	7.0×	9.6×	7th cheapest of 15
Growth the price implies (Req g, 7 yrs)	31.6%	n/a	—
Growth delivered (Del g)	+7.0%	n/a	—
Hurdle (Req g minus delivered)	+24.6 pp	n/a	—
ROIC minus cost of capital	-1.8 pp	-11.3 pp	3rd highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Sinotherapeutics 688247.SS	China	$537M	-14%	-17%	0%	7.0×	31.6%	+7.0%
Valneva VLA.PA	France	$534M	-2%	-27%	-87%	4.0×	n/a	n/a
Hvsen Biotechnology 300871.SZ	China	$531M	-33%	+2%	17%	2.2×	n/a	n/a
Liaoning Dingjide Petrochemical 603255.SS	China	$530M	-15%	+70%	5%	5.4×	n/a	n/a
Beijing Scitop Bio-Tech 300858.SZ	China	$526M	-25%	+4%	8%	8.0×	n/a	n/a
Beijing Bohui Innovation Biotechnology 300318.SZ	China	$553M	-19%	+6%	-11%	6.5×	n/a	n/a
LongBio Pharma (Suzhou) 1779.HK	Hong Kong	$554M	n/a	n/a	n/a	n/a	n/a	n/a
HanchorBio 7827.TW	Taiwan	$511M	n/a	n/a	-225%	48.0×	n/a	n/a
Faeth Therapeutics FTH	United States	$570M	-6%	n/a	n/a	n/a	n/a	n/a
Shanghai Serum Bio-Technology 688163.SS	China	$507M	-11%	-1%	26%	13.7×	n/a	n/a
Neurogene NGNE	United States	$506M	-18%	-100%	n/a	n/a	n/a	n/a
DiaMedica Therapeutics DMAC	United States	$505M	+48%	n/a	n/a	n/a	n/a	n/a
Berry Genomics 000710.SZ	China	$504M	-5%	-2%	-24%	3.8×	n/a	n/a
Qurient 115180.KS	South Korea	$503M	-59%	-20%	-517%	98.9×	n/a	n/a
Crescent Biopharma CBIO	United States	$503M	-28%	n/a	-1,418%	28.3×	n/a	n/a
Alebund Pharmaceuticals (Jiangsu) 9637.HK	Hong Kong	$576M	n/a	+674%	-495%	25.7×	n/a	n/a
Climb Bio CLYM	United States	$591M	-10%	n/a	n/a	n/a	n/a	n/a
Genfit GNFT.PA	France	$593M	+19%	+28%	-130%	11.2×	40.0%	+143.5%
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	8,168.1×	n/a	n/a
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a

Questions

Which companies are Sinotherapeutics's closest peers?: The cockpit's peer set: Valneva (VLA.PA), Hvsen Biotechnology (300871.SZ), Liaoning Dingjide Petrochemical (603255.SS), Beijing Scitop Bio-Tech (300858.SZ), Beijing Bohui Innovation Biotechnology (300318.SZ), LongBio Pharma (Suzhou) (1779.HK), HanchorBio (7827.TW), Faeth Therapeutics (FTH).
Is Sinotherapeutics expensive compared with its peers?: On ev / sales it trades at 7.0× against a peer median of 9.6×, 7th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sinotherapeutics stock performed?: Over six months to 6 Nov 2026 the shares returned -14.2% against -9.5% for the median peer; over one year -26.2%.